Serum-Based Diagnostic for Assessing Mild Traumatic Brain Injury

Easily administered and accurate diagnostic.Ensures proper diagnosis.Does not rely on UCHL1 biomarker.
  • Easily administered and accurate diagnostic.
  • Ensures proper diagnosis.
  • Does not rely on UCHL1 biomarker.


Technology Description

Inventors at the University of Iowa have developed a panel of biomarkers that can be used to diagnose mild traumatic brain injury (mTBI). Currently, the biomarker UCHL1 is FDA approved for diagnosis of mTBI. However, in animal studies UCHL1 is not secreted during mild injury calling into question its use in diagnosing mTBI. Studies at UI reveal that certain biomarkers are expressed in the mouse brain after exposure to a mTBI and translocate through the blood-brain barrier to the bloodstream. Once in the blood stream, an immune response generates antibodies against the proteins. Antibodies against the biomarkers can be used to easily diagnosis patients with mTBI. Having a routine, accurate and easily administered diagnostic test will help ensure proper diagnosis for patients suffering from mTBI and improve long term prognosis.

UIRF Case No. 2019-032

Stage of Development

Biomarkers have been tested in a murine model of TBI.



  • Could help reduce up to 50% of deaths due to TBI.
  • Easily administered serum-based test.
  • More reliable than current mTBI biomarker.
  • Can help reduce long term medical and rehabilitation costs.

Contact Information:

Name: Kellen Sensor

Title :

Department :


Phone: 319.335.4546

Address :